Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News EOM Pharmaceutical Holdings Inc IMUC

Healthcare Biotechnology
EOM Pharmaceutical Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing novel drugs for patients suffering from debilitating and deadly diseases, including infectious diseases; autoimmune diseases including rheumatoid arthritis; and cachexia associated with acquired immune deficiency syndrome (AIDS) and cancer. It has two pipeline assets in their... see more

Recent & Breaking News (PINL:IMUC)

EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613

PR Newswire November 7, 2023

EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil

PR Newswire September 6, 2023

Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors

GlobeNewswire October 3, 2022

EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement

PR Newswire December 2, 2021

ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market

PR Newswire June 28, 2021

ImmunoCellular Therapeutics Announces Results of Special Meeting of Stockholders Held June 26, 2020

PR Newswire July 2, 2020

ImmunoCellular Therapeutics Announces Settlement of Derivative Action Lawsuit

PR Newswire October 16, 2019

ImmunoCellular Therapeutics Announces Completion of Asset Purchase Transaction with Private Biotechnology Company

PR Newswire August 28, 2019

ImmunoCellular Therapeutics: Notice of Proposed Settlement of Derivative Action

GlobeNewswire August 9, 2019

ImmunoCellular Therapeutics Announces Asset Purchase Agreement with Private Biotechnology Company

PR Newswire July 16, 2019

ImmunoCellular Announces Receipt of Notice of Noncompliance with The NYSE American Continued Listing Standards

PR Newswire October 17, 2018

ImmunoCellular Therapeutics Announces Delisting and Deregistration of Common Stock and Listed Common Stock Warrants

PR Newswire October 15, 2018

New Research Coverage Highlights K12, ImmunoCellular Therapeutics, The First of Long Island, Blue Bird, The Providence Service, and German American — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire September 5, 2018

ImmunoCellular Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results

PR Newswire August 13, 2018

ImmunoCellular Therapeutics Announces First Quarter 2018 Financial Results

PR Newswire May 14, 2018

ImmunoCellular Therapeutics Announces NYSE MKT Acceptance of its Plan of Compliance

PR Newswire September 13, 2017

ImmunoCellular Therapeutics Provides Business Update on Research and Development Programs and Future Strategy

PR Newswire August 23, 2017

ImmunoCellular Therapeutics Announces Second Quarter 2017 Financial Results

PR Newswire August 14, 2017

Daily Technical Summary Reports on Biotech Stocks -- Axovant Sciences, Ampio Pharma, ImmunoCellular Therapeutics, and Synthetic Biologics

PR Newswire August 9, 2017

ImmunoCellular Therapeutics Announces Pricing of Public Offering of Convertible Preferred Stock and Warrants

PR Newswire July 18, 2017